Using REMS to Ram Drugs through FDA Faster
This article was originally published in RPM Report
Executive Summary
FDA's use of Risk Evaluation & Mitigation Strategies will require NDA and BLA sponsors to provide more rigorous definitions of patient populations. Former FDA Commissioner Kessler thinks that may break the logjam on approvals.
You may also be interested in...
The REMS Era Begins: FDA Applies Soft Touch With New Drug Safety Tools
Congress gave FDA some tough new tools to regulate drugs in September, but no one could know for sure how FDA would use them. Now there is some actual real world experience to judge by: a half-dozen drugs approved by FDA are subject to either a Risk Evaluation & Mitiagation Strategy or a mandatory post-marketing commitment. So far, the news is good for drug developers.
Food for Thought: The Case for Two FDAs
Is it time to rethink the combination of food regulation with drugs and devices? One powerful member of Congress thinks so. The separation could be good for FDA, and maybe for biopharma companies too. But it is also a distraction at a bad time for the agency.
The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Drug Approvals
Pharma is adjusting rapidly to a new regulatory world: one in which post-marketing risk management plans change the relationship of the company to doctors and patients and one where FDA's expectations for pre-marketing information about product markets are likely to expand dramatically.